C07K 7/083
Neurotensin
Official title: {Neurotensin}
C07K7/083 (Neurotensin) appears on 45 US grants and 62 published applications in this corpus.
Search patents in C07K- Granted patents
- 45
- Published applications
- 62
- Assignees
- 46
- Inventors
- 153
- Latest grant
- 23 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 2 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 2 | 0 |
| 1995 | 2 | 0 |
| 1996 | 2 | 0 |
| 1997 | 0 | 0 |
| 1998 | 3 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 2 | 1 |
| 2002 | 0 | 1 |
| 2003 | 2 | 2 |
| 2004 | 1 | 1 |
| 2005 | 2 | 5 |
| 2006 | 2 | 1 |
| 2007 | 1 | 3 |
| 2008 | 0 | 2 |
| 2009 | 0 | 1 |
| 2010 | 1 | 2 |
| 2011 | 0 | 3 |
| 2012 | 0 | 5 |
| 2013 | 2 | 5 |
| 2014 | 0 | 1 |
| 2015 | 0 | 2 |
| 2016 | 2 | 2 |
| 2017 | 2 | 2 |
| 2018 | 1 | 1 |
| 2019 | 2 | 1 |
| 2020 | 0 | 4 |
| 2021 | 1 | 0 |
| 2022 | 1 | 4 |
| 2023 | 2 | 3 |
| 2024 | 1 | 4 |
| 2025 | 4 | 5 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Chimeric polypeptides and uses thereof23 Jun 2026US 12,662,512 B2Genethon
- Human blood-brain barrier targeting antibodies9 Dec 2025US 12,492,251 B2Wisconsin Alumni Research Foundation
- Radiopharmaceuticals and methods of use thereof2 Dec 2025US 12,485,191 B2Board of Regents of the Univeristy of Nebraska
- Peptide useful for the transport of molecules through cell barriers11 Nov 2025US 12,466,854 B2Institut National de la Sante et de la Recherche Medicale
- Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy8 Apr 2025US 12,269,902 B2Transfert Plus, S.E.C.
- Human blood-brain barrier targeting antibodies5 Mar 2026US 2026/0062480 A1Wisconsin Alumni Research Foundation
- Bifunctional molecules that selectively induce degradation of extracellular targets in lysosomes13 Nov 2025US 2025/0345446 A1Draupnir Bio ApS
- Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy25 Sep 2025US 2025/0296957 A1Transfert Plus, S.E.C.
- Peptide analogs15 May 2025US 2025/0154219 A1Adepthera LLC
- Dual agonist glp-1 and neurotensin fusion peptide17 Apr 2025US 2025/0122239 A1
Most cited
By later US patents
- Lyophilized polyethylene oxide modified protein and polypeptide complexes with cyclodextrin129US 5,529,915 ASterling Winthrop Inc. · 1996
- Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life69US 5,298,410 ASterling Winthrop Inc. · 1994
- Neo-tryptophan35US 6,214,790 B1Mayo Foundation for Medical Education and Research · 2001
- Vasoactive intestinal peptide antagonist17US 5,217,953 AThe United States of America, as represented by the Secretary, Department of Health and Human Services · 1993
- Short-chain peptide-dye conjugates as contrast media for optical diagnosis17US 6,630,570 B1Insitut für Diagnostikforschung GmbH · 2003